Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital

Introduction Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer patients are scarce. Method This prospective, age- and sex-matched, single-center cohort stu...

Descripción completa

Detalles Bibliográficos

Autores principales:	Piyarat Limpawittayakul, Prakongboon Sungkasubun, Worawit Chaiwiriyawong, Archara Supavavej, Bowon Weerasubpong, Jomtana Siripaibun, Chumut Phanthunane, Wisut Lamlertthon, Teerapat Ungtrakul, Kriangkrai Tawinprai, Walaipan Tantiyavarong, Chayanee Samdaengpan
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2022-11-01
Colección:	Human Vaccines & Immunotherapeutics
Materias:	chadox1 ncov-19 azd1222 vaccine solid cancer seropositivity titer
Acceso en línea:	http://dx.doi.org/10.1080/21645515.2022.2104058
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!